This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Breccia, M. Articles by Coco, F. L. Search for Related Content PubMed PubMed Citation Articles by Breccia, M. Articles by Coco, F. L.

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy (MB, GC, DD, FG,FM); Department of Biopathology, University of Tor Vergata, Rome, Italy (FL-C)

Correspondence: Massimo Breccia, MD, Dept. of Human Biotechnology and Hematology, Via Benevento 6, 00161 Rome, Italy. Phone: international +39.06.857951. Fax: international +39.06.44241984. E-mail: breccia{at}bce.uniroma1.it

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m²) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

Key words: acute promyelocytic leukemia, gentuzumab ozogamicin, molecular relapse.

This article has been cited by other articles:

				M. S. Tallman and J. K. Altman How I treat acute promyelocytic leukemia Blood, December 10, 2009; 114(25): 5126 - 5135. [Abstract] [Full Text] [PDF]

				F. Ravandi, E. Estey, D. Jones, S. Faderl, S. O'Brien, J. Fiorentino, S. Pierce, D. Blamble, Z. Estrov, W. Wierda, et al. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin J. Clin. Oncol., February 1, 2009; 27(4): 504 - 510. [Abstract] [Full Text] [PDF]